⌕
GSK · GSK · NYSE
Tenet 51 · Mixed
Compare
$50.89+0.87%Market openTenet 51 · Mixed
$50.89+0.44 (+0.87%)
Market open · as of 11:07 AM ET· NYSE · USD

GSK News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is GSK's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 14, 2026 · 04:41 ET
Critical Survey: GSK (NYSE:GSK) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

GSK (NYSE: GSK - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength …

GSK +0.9% todayRead at source ↗
● MarketBeatNov 9, 2026 · 14:15 ET
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments

GSK NYSE: GSK is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, a senior research ex…

GSK +0.9% todayRead at source ↗
● ReutersNov 6, 2026 · 13:14 ET
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots

GSK, Moderna settle patent dispute over Moderna COVID, RSV shots…

GSK +0.9% todayRead at source ↗
● New York PostNov 4, 2026 · 12:37 ET
HP taps Emma Walmsley, ex-GSK chief and Microsoft board member, as CEO

HP, like peers Dell Technologies, Apple and Lenovo, is caught in a global memory chip squeeze.…

GSK +0.9% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 16:03 ET
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine

FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific…

GSK +0.9% todayRead at source ↗
● Seeking AlphaOct 30, 2026 · 00:38 ET
GSK: The Gas Pedal Is Still Down, But Bumps Ahead

Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines revenue rose 14%, helping …

GSK +0.9% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 13:26 ET
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.…

GSK +0.9% todayRead at source ↗
● Seeking AlphaOct 28, 2026 · 14:40 ET
GSK plc (GSK) Q3 2026 Earnings Call Transcript

GSK plc ( GSK ) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations Luke Miels - CEO & Director Tony Wood - Chief Scient…

GSK +0.9% todayRead at source ↗
● MarketBeatOct 28, 2026 · 14:06 ET
What GSK (GSK) Said on Its Q3 Earnings Call

GSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while co…

GSK +0.9% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 12:46 ET
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales

GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.…

GSK +0.9% todayRead at source ↗
● BenzingaOct 28, 2026 · 11:45 ET
GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat

GSK Plc (NYSE:GSK) reported third-quarter adjusted earnings of $1.47 per share (54.6 pence), beating the analyst consensus estimate of $1.40.…

GSK +0.9% todayRead at source ↗
● Seeking AlphaOct 28, 2026 · 10:57 ET
GSK: Why I'm Still Bullish After Strong Q3 Results

GSK plc delivered strong results today. In the third quarter, revenue and non-GAAP EPS grew 5.7% and 8.2% quarter-on-quarter, respectively. Cabenuva, GSK's long-acting HIV treatment, generated $641 million in sales, up 3…

GSK +0.9% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 08:11 ET
GSK (GSK) Q3 Earnings and Revenues Beat Estimates

GSK (GSK) came out with quarterly earnings of $1.47 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.48 per share a year ago.…

GSK +0.9% todayRead at source ↗
● WSJOct 28, 2026 · 04:02 ET
GSK Sales Get Boost From Specialty Medicines

The U.K. drugmaker's strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.…

GSK +0.9% todayRead at source ↗
● ReutersOct 28, 2026 · 03:13 ET
GSK beats third-quarter profit estimates, keeps annual targets

GSK beat third-quarter sales and profit expectations ​on Wednesday, helped ‌by demand for specialty medicines, suggesting CEO Luke Miels' efforts ​to accelerate growth ​and prepare the drugmaker ⁠for…

GSK +0.9% todayRead at source ↗
● Seeking AlphaOct 27, 2026 · 17:19 ET
GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript…

GSK +0.9% todayRead at source ↗
● MarketBeatOct 27, 2026 · 14:06 ET
GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update

GSK NYSE: GSK highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 antibody-drug conjugate ris-rez, B7-H4 ADC mo-rez, PD-1 therapy d…

GSK +0.9% todayRead at source ↗
● ReutersOct 27, 2026 · 03:47 ET
GSK to nearly double cancer drugs in trials, WSJ reports

GSK expects ​to nearly ‌double the number ​of cancer ​medicines it is ⁠testing ​in clinical ​trials next year, the ​Wall ​Street Journal reported ‌on ⁠Tuesday, citing an interview with ​a ​scientist…

GSK +0.9% todayRead at source ↗
● WSJOct 27, 2026 · 03:31 ET
GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

EXCLUSIVE: The U.K. drugmaker currently has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.…

GSK +0.9% todayRead at source ↗
● 24/7 Wall StreetOct 24, 2026 · 11:08 ET
Can Specialty Meds Offset GSK's $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28?

GSK (NYSE:GSK | GSK Price Prediction) reports third-quarter results on October 28. A $2.…

GSK +0.9% todayRead at source ↗
● Zacks Investment ResearchOct 21, 2026 · 11:01 ET
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

GSK +0.9% todayRead at source ↗
● Proactive InvestorsOct 21, 2026 · 08:37 ET
GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies says

Jefferies has reiterated its 'buy' rating on GSK PLC (LSE:GSK, NYSE:GSK), the pharmaceutical company, with a 2,500p price target after US regulators approved its hepatitis B treatment, Hibsago. The target represents a po…

GSK +0.9% todayRead at source ↗
● Business WireOct 20, 2026 · 19:58 ET
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in …

GSK +0.9% todayRead at source ↗
● ReutersOct 20, 2026 · 16:04 ET
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment

US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment…

GSK +0.9% todayRead at source ↗
● Zacks Investment ResearchOct 20, 2026 · 11:26 ET
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth

GSK's newer drugs, expanding indications and promising pipeline could drive long-term growth, with sales expected to exceed 40 billion pounds by 2031.…

GSK +0.9% todayRead at source ↗
● Business WireOct 9, 2026 · 08:01 ET
Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with GSK.…

GSK +0.9% todayRead at source ↗
● PRNewsWireOct 8, 2026 · 07:38 ET
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk

For the first time, Viola Davis shares her experience with shingles Viola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come with aging The partn…

GSK +0.9% todayRead at source ↗
● GlobeNewsWireSep 30, 2026 · 07:30 ET
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development

Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing…

GSK +0.9% todayRead at source ↗
● Business WireSep 28, 2026 · 07:00 ET
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry…

GSK +0.9% todayRead at source ↗
● Business WireAug 26, 2026 · 09:00 ET
Noetik Achieves First Milestone in Landmark GSK Collaboration

SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--Noetik achieves first milestone in landmark GSK collaboration.…

GSK +0.9% todayRead at source ↗

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA9−2.3%
ABR2−5.6%
ARMK2−1.0%
BBWI2−7.3%

Article counts from the last market-wide feed page, across every symbol we track and not just GSK · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.